Home / Hyaluronic acid injections

HAXL One: cross-linked hyaluronic acid injection

Information page — not an availability announcement. HAXL One is being reviewed as a potential treatment option. Contact the clinic to establish which treatments are currently available and suitable for you.

What is HAXL One?

HAXL One is a sterile, intra-articular preparation of cross-linked sodium hyaluronate (2%). It is designed for injection into a joint. It differs in formulation from Ostenil Plus, which uses non-chemically modified sodium hyaluronate. The products should not be treated as interchangeable without checking their individual instructions for use, indications and suitability.

Manufacturer's product instructions (PDF).

How does it compare with Ostenil Plus?

Ostenil Plus is a 2% non-chemically modified sodium hyaluronate preparation; HAXL One is cross-linked. Cross-linking changes the formulation's physical properties, but does not by itself prove better pain relief, longer-lasting benefit or cost-effectiveness for a particular patient.

A 2026 systematic review and network meta-analysis of 66 trials (9,822 participants) found that independent benefits attributable specifically to cross-linking were not established. Differences between formulations remain uncertain.

What does the research say?

One 2026 comparative cohort study of 120 patients reported greater improvements at six months with a 4.4 mL cross-linked hyaluronic acid formulation than with hylastan SGL-80. This is encouraging but does not establish superiority over Ostenil Plus, Durolane, placebo or usual care, and a single study cannot settle the broader evidence debate.

A 2019 randomised trial found Ostenil Plus non-inferior to hylan G-F 20 at six months; this study was sponsored by TRB Chemedica. Conversely, a placebo-controlled trial of another hyaluronan product found no clinically meaningful benefit. Results cannot automatically be transferred between formulations.

UK guidance: NICE NG226 advises not offering intra-articular hyaluronan injections for osteoarthritis. Patients should be told this when considering private treatment. Exercise and supported self-management remain central to care.

Clinical assessment and safety

Injection decisions should follow assessment, discussion of realistic outcomes and alternatives, product-specific contraindications and informed consent. Risks include post-injection pain or swelling, infection and allergic reactions. A joint injection is not a cure for osteoarthritis.

Explore hyaluronic acid injections · Physiotherapy and rehabilitation

Research and sources

  1. Meccariello, L. et al. (2026). Clinical efficacy of 4.4 mL single-dose intra-articular cross-linked hyaluronic acid injection in patients with knee osteoarthritis. European Journal of Translational Myology. doi:10.4081/ejtm.2026.15626.
  2. Beyond molecular weight: formulation characteristics and structural disease severity as modifiers of response to intra-articular hyaluronic acid for knee osteoarthritis (2026). Systematic review and component network meta-analysis. doi:10.1016/j.jcjp.2026.100327.
  3. Maheu, E. et al. (2019). A single intra-articular injection of 2.0% non-chemically modified sodium hyaluronate vs 0.8% hylan G-F 20 in symptomatic knee osteoarthritis: randomised controlled non-inferiority trial. PLOS ONE. doi:10.1371/journal.pone.0226007.
  4. Jørgensen, A. et al. (2010). Intra-articular hyaluronan is without clinical effect in knee osteoarthritis: randomised placebo-controlled study. Annals of the Rheumatic Diseases. doi:10.1136/ard.2009.118042.
  5. National Institute for Health and Care Excellence (2022). Osteoarthritis in over 16s: management (NG226). NICE guideline.

Evidence last checked: 14 October 2026. Product-specific prescribing/administration decisions must follow current instructions for use and local clinical governance.